Featured Research

from universities, journals, and other organizations

Risk measurement tool for heart attacks and strokes updated

Date:
August 26, 2011
Source:
European Society of Cardiology (ESC)
Summary:
The number of heart attack and stroke incidents in Europe is likely to reduce with the imminent launch of an update to the HeartScore® application. HeartScore® helps clinicians rapidly estimate the risk of cardiovascular disease (CVD) in individual patients using age, gender, basic health indicators, and lifestyle factors. The results from the model are then used to shape intervention and advice regimes aimed at lowering CVD risk. Following feedback, HeartScore® has been updated to incorporate a number of new features that will enhance its value as part of CVD prevention strategies.

The number of heart attack and stroke incidents in Europe is likely to reduce with the imminent launch of an update to the HeartScore® application. HeartScore® was first developed by the European Society of Cardiology (ESC) in 2004, and it helps clinicians rapidly estimate the risk of cardiovascular disease (CVD) in individual patients using age, gender, basic health indicators, and lifestyle factors. The results from the model are then used to shape intervention and advice regimes aimed at lowering CVD risk. Following feedback, HeartScore® has been updated to incorporate a number of new features that will enhance its value as part of CVD prevention strategies.

Professor Ian Graham is Chair of the Prevention Implementation Committee of the ESC's European Association of Cardiovascular Prevention and Rehabilitation (EACPR), and is project leader for HeartScore®. "This important update continues our work to develop a practical tool for accessible CVD risk estimation," he says. "Clinicians have told us that, above all, they want accurate, fast and simple information that is relevant to them and their patients. I am confident that this new release of HeartScore® will meet those needs and benefit patients everywhere."

Three variants of the updated HeartScore® will be formally released at the 2011 ESC Congress in Paris (26 -- 30 August). These are European models for both high and low risk, and a variant for France -- the 15th national version to be developed. The new features include:

  • A refinement that allows clinicians the option to enter the actual HDL cholesterol level rather than the combined HDL/LDL cholesterol level -- this step improves the accuracy of the model, especially in marginal cases
  • A 'fast track' calculator in which Body Mass Index (BMI) replaces blood pressure and cholesterol inputs -- this is intended only for when blood pressure and cholesterol are not available and provides only a preliminary assessment
  • A 'risk age' function that determines the theoretical age of a person exposed to the same range and level of risk factors -- this will help patients quickly understand their exposure to overall CVD risk

Around 26,000 medical professionals across Europe are already using HeartScore® which has been adapted into 14 national versions to support specific local requirements including language and, when appropriate, to meet mortality rates of individual countries. The application is available online or as a download from the HeartScore® website at www.heartscore.org. Predictions of CVD risk are based on the ESC's SCORE (Systemic Coronary Risk Evaluation) model which is itself based on the 2007 ESC Guidelines on CVD prevention. HeartScore® conducts a real-time statistical analysis of data entered by the clinician. Results are available immediately and can be archived for future comparisons and progress monitoring.

The model provides a simple graphical display of absolute CVD risk together with tailored information on intervention areas, a discussion on the relevant risk factors, and a printed advice pack for the patient that explains the analysis and encourages shifts in behaviour and lifestyle when appropriate.


Story Source:

The above story is based on materials provided by European Society of Cardiology (ESC). Note: Materials may be edited for content and length.


Cite This Page:

European Society of Cardiology (ESC). "Risk measurement tool for heart attacks and strokes updated." ScienceDaily. ScienceDaily, 26 August 2011. <www.sciencedaily.com/releases/2011/08/110826111515.htm>.
European Society of Cardiology (ESC). (2011, August 26). Risk measurement tool for heart attacks and strokes updated. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/08/110826111515.htm
European Society of Cardiology (ESC). "Risk measurement tool for heart attacks and strokes updated." ScienceDaily. www.sciencedaily.com/releases/2011/08/110826111515.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins